#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=Rarely , such influenza vaccines can cause allergic reactions such as hives , rapid swelling of deeper skin layers and tissues , asthma or a severe multisystem allergic reaction due to hypersensitivity to certain vaccine components .
1-1	0-6	Rarely	_	_	_	_
1-2	7-8	,	_	_	_	_
1-3	9-13	such	substance[2]	new[2]	coref	2-2[0_2]
1-4	14-23	influenza	abstract|substance[2]	new|new[2]	coref	3-12
1-5	24-32	vaccines	substance[2]	new[2]	_	_
1-6	33-36	can	_	_	_	_
1-7	37-42	cause	_	_	_	_
1-8	43-51	allergic	event[3]	new[3]	_	_
1-9	52-61	reactions	event[3]	new[3]	_	_
1-10	62-66	such	event[3]	new[3]	_	_
1-11	67-69	as	event[3]	new[3]	_	_
1-12	70-75	hives	event[3]|abstract	new[3]|new	_	_
1-13	76-77	,	event[3]	new[3]	_	_
1-14	78-83	rapid	event[3]|event[5]	new[3]|new[5]	_	_
1-15	84-92	swelling	event[3]|event[5]	new[3]|new[5]	_	_
1-16	93-95	of	event[3]|event[5]	new[3]|new[5]	_	_
1-17	96-102	deeper	event[3]|event[5]|abstract[7]	new[3]|new[5]|new[7]	_	_
1-18	103-107	skin	event[3]|event[5]|object|abstract[7]	new[3]|new[5]|new|new[7]	_	_
1-19	108-114	layers	event[3]|event[5]|abstract[7]	new[3]|new[5]|new[7]	_	_
1-20	115-118	and	event[3]|event[5]	new[3]|new[5]	_	_
1-21	119-126	tissues	event[3]|event[5]|object	new[3]|new[5]|new	_	_
1-22	127-128	,	event[3]	new[3]	_	_
1-23	129-135	asthma	event[3]|abstract	new[3]|new	_	_
1-24	136-138	or	event[3]	new[3]	_	_
1-25	139-140	a	event[3]|abstract[11]	new[3]|new[11]	_	_
1-26	141-147	severe	event[3]|abstract[11]	new[3]|new[11]	_	_
1-27	148-159	multisystem	event[3]|abstract|abstract[11]	new[3]|new|new[11]	_	_
1-28	160-168	allergic	event[3]|abstract[11]	new[3]|new[11]	_	_
1-29	169-177	reaction	event[3]|abstract[11]	new[3]|new[11]	_	_
1-30	178-181	due	_	_	_	_
1-31	182-184	to	_	_	_	_
1-32	185-201	hypersensitivity	abstract[12]	new[12]	_	_
1-33	202-204	to	abstract[12]	new[12]	_	_
1-34	205-212	certain	abstract[12]|substance[14]	new[12]|new[14]	_	_
1-35	213-220	vaccine	abstract[12]|substance|substance[14]	new[12]|new|new[14]	coref	5-23
1-36	221-231	components	abstract[12]|substance[14]	new[12]|new[14]	_	_
1-37	232-233	.	_	_	_	_

#Text=Live vaccines are given via a nasal spray , and can commonly cause runny nose , nasal congestion , cough , and can less frequently cause sore throat , low grade fever , irritability and head- and muscle- aches .
2-1	234-238	Live	_	_	_	_
2-2	239-247	vaccines	substance	giv	coref	3-11[29_0]
2-3	248-251	are	_	_	_	_
2-4	252-257	given	_	_	_	_
2-5	258-261	via	_	_	_	_
2-6	262-263	a	object[16]	new[16]	_	_
2-7	264-269	nasal	object[16]	new[16]	_	_
2-8	270-275	spray	object[16]	new[16]	_	_
2-9	276-277	,	_	_	_	_
2-10	278-281	and	_	_	_	_
2-11	282-285	can	_	_	_	_
2-12	286-294	commonly	_	_	_	_
2-13	295-300	cause	_	_	_	_
2-14	301-306	runny	object[17]	new[17]	_	_
2-15	307-311	nose	object[17]	new[17]	_	_
2-16	312-313	,	_	_	_	_
2-17	314-319	nasal	object[18]	new[18]	_	_
2-18	320-330	congestion	object[18]	new[18]	_	_
2-19	331-332	,	_	_	_	_
2-20	333-338	cough	abstract	new	_	_
2-21	339-340	,	_	_	_	_
2-22	341-344	and	_	_	_	_
2-23	345-348	can	_	_	_	_
2-24	349-353	less	_	_	_	_
2-25	354-364	frequently	_	_	_	_
2-26	365-370	cause	_	_	_	_
2-27	371-375	sore	object[20]	new[20]	_	_
2-28	376-382	throat	object[20]	new[20]	_	_
2-29	383-384	,	_	_	_	_
2-30	385-388	low	abstract[22]	new[22]	_	_
2-31	389-394	grade	abstract|abstract[22]	new|new[22]	_	_
2-32	395-400	fever	abstract[22]	new[22]	_	_
2-33	401-402	,	_	_	_	_
2-34	403-415	irritability	abstract	new	_	_
2-35	416-419	and	_	_	_	_
2-36	420-425	head-	object	new	_	_
2-37	426-429	and	_	_	_	_
2-38	430-437	muscle-	abstract[25]	new[25]	_	_
2-39	438-443	aches	abstract[25]	new[25]	_	_
2-40	444-445	.	_	_	_	_

#Text=Wheezing and vomiting episodes have been described in children receiving live influenza vaccines .
3-1	446-454	Wheezing	_	_	_	_
3-2	455-458	and	_	_	_	_
3-3	459-467	vomiting	abstract[26]	new[26]	_	_
3-4	468-476	episodes	abstract[26]	new[26]	_	_
3-5	477-481	have	_	_	_	_
3-6	482-486	been	_	_	_	_
3-7	487-496	described	_	_	_	_
3-8	497-499	in	_	_	_	_
3-9	500-508	children	person	new	coref	20-26[178_0]
3-10	509-518	receiving	_	_	_	_
3-11	519-523	live	substance[29]	giv[29]	coref	4-18[0_29]
3-12	524-533	influenza	abstract|substance[29]	giv|giv[29]	coref	13-22
3-13	534-542	vaccines	substance[29]	giv[29]	_	_
3-14	543-544	.	_	_	_	_

#Text=( ( MM ) ) What action has the WHO taken , if any , to insure vaccines are available ?
4-1	545-546	(	_	_	_	_
4-2	547-548	(	_	_	_	_
4-3	549-551	MM	person	new	coref	12-3
4-4	552-553	)	_	_	_	_
4-5	554-555	)	_	_	_	_
4-6	556-560	What	abstract[31]	new[31]	_	_
4-7	561-567	action	abstract[31]	new[31]	_	_
4-8	568-571	has	_	_	_	_
4-9	572-575	the	_	_	_	_
4-10	576-579	WHO	_	_	_	_
4-11	580-585	taken	_	_	_	_
4-12	586-587	,	_	_	_	_
4-13	588-590	if	_	_	_	_
4-14	591-594	any	_	_	_	_
4-15	595-596	,	_	_	_	_
4-16	597-599	to	_	_	_	_
4-17	600-606	insure	_	_	_	_
4-18	607-615	vaccines	substance	giv	coref	6-27[52_0]
4-19	616-619	are	_	_	_	_
4-20	620-629	available	_	_	_	_
4-21	630-631	?	_	_	_	_

#Text=( ( KM ) ) During the first stages of the pandemic in 2009 , the Director-General highlighted the need to make vaccine and medicines available to countries who would be unable to access them on their own .
5-1	632-633	(	_	_	_	_
5-2	634-635	(	_	_	_	_
5-3	636-638	KM	quantity	new	coref	13-3
5-4	639-640	)	_	_	_	_
5-5	641-642	)	_	_	_	_
5-6	643-649	During	_	_	_	_
5-7	650-653	the	_	_	_	_
5-8	654-659	first	_	_	_	_
5-9	660-666	stages	abstract	new	ana	5-35
5-10	667-669	of	_	_	_	_
5-11	670-673	the	event[35]	new[35]	coref	6-4[0_35]
5-12	674-682	pandemic	event[35]	new[35]	_	_
5-13	683-685	in	_	_	_	_
5-14	686-690	2009	time	new	coref	25-3
5-15	691-692	,	_	_	_	_
5-16	693-696	the	person[37]	new[37]	_	_
5-17	697-713	Director-General	person[37]	new[37]	_	_
5-18	714-725	highlighted	_	_	_	_
5-19	726-729	the	abstract[38]	new[38]	_	_
5-20	730-734	need	abstract[38]	new[38]	_	_
5-21	735-737	to	_	_	_	_
5-22	738-742	make	_	_	_	_
5-23	743-750	vaccine	substance	giv	coref	6-5
5-24	751-754	and	_	_	_	_
5-25	755-764	medicines	substance[40]	new[40]	_	_
5-26	765-774	available	substance[40]	new[40]	_	_
5-27	775-777	to	_	_	_	_
5-28	778-787	countries	place	new	coref	6-12[48_0]
5-29	788-791	who	_	_	_	_
5-30	792-797	would	_	_	_	_
5-31	798-800	be	_	_	_	_
5-32	801-807	unable	_	_	_	_
5-33	808-810	to	_	_	_	_
5-34	811-817	access	_	_	_	_
5-35	818-822	them	abstract	giv	ana	5-37
5-36	823-825	on	_	_	_	_
5-37	826-831	their	abstract	giv	_	_
5-38	832-835	own	_	_	_	_
5-39	836-837	.	_	_	_	_

#Text=As the WHO pandemic vaccine donation programme was first established , all countries were surveyed by WHO , and 95 identified as having no access to pandemic vaccines , and therefore eligible for donations .
6-1	838-840	As	_	_	_	_
6-2	841-844	the	abstract[47]	new[47]	_	_
6-3	845-848	WHO	abstract[47]	new[47]	_	_
6-4	849-857	pandemic	event|abstract[47]	giv|new[47]	coref	6-27
6-5	858-865	vaccine	substance|abstract[47]	giv|new[47]	coref	7-6[55_0]
6-6	866-874	donation	abstract|abstract[47]	new|new[47]	_	_
6-7	875-884	programme	abstract[47]	new[47]	_	_
6-8	885-888	was	_	_	_	_
6-9	889-894	first	_	_	_	_
6-10	895-906	established	_	_	_	_
6-11	907-908	,	_	_	_	_
6-12	909-912	all	place[48]	giv[48]	coref	7-29[62_48]
6-13	913-922	countries	place[48]	giv[48]	_	_
6-14	923-927	were	_	_	_	_
6-15	928-936	surveyed	_	_	_	_
6-16	937-939	by	_	_	_	_
6-17	940-943	WHO	_	_	_	_
6-18	944-945	,	_	_	_	_
6-19	946-949	and	_	_	_	_
6-20	950-952	95	person	new	_	_
6-21	953-963	identified	_	_	_	_
6-22	964-966	as	_	_	_	_
6-23	967-973	having	_	_	_	_
6-24	974-976	no	abstract[50]	new[50]	_	_
6-25	977-983	access	abstract[50]	new[50]	_	_
6-26	984-986	to	abstract[50]	new[50]	_	_
6-27	987-995	pandemic	abstract[50]|event|substance[52]	new[50]|giv|giv[52]	coref|coref|coref|coref	7-20[59_52]|8-12[78_0]|7-20[59_52]|8-12[78_0]
6-28	996-1004	vaccines	abstract[50]|substance[52]	new[50]|giv[52]	_	_
6-29	1005-1006	,	_	_	_	_
6-30	1007-1010	and	_	_	_	_
6-31	1011-1020	therefore	_	_	_	_
6-32	1021-1029	eligible	_	_	_	_
6-33	1030-1033	for	_	_	_	_
6-34	1034-1043	donations	object	new	_	_
6-35	1044-1045	.	_	_	_	_

#Text=Based on the pledges of donated vaccine , a plan was prepared for a two phase approach to supply sufficient vaccines for 10 % of the population in these countries ; an initial supply to cover health workers and other essential workers , equivalent to 2 % of the population , and a second supply of 8 % for other priority groups .
7-1	1046-1051	Based	_	_	_	_
7-2	1052-1054	on	_	_	_	_
7-3	1055-1058	the	abstract[54]	new[54]	_	_
7-4	1059-1066	pledges	abstract[54]	new[54]	_	_
7-5	1067-1069	of	abstract[54]	new[54]	_	_
7-6	1070-1077	donated	abstract[54]|substance[55]	new[54]|giv[55]	coref	9-8[84_55]
7-7	1078-1085	vaccine	abstract[54]|substance[55]	new[54]|giv[55]	_	_
7-8	1086-1087	,	_	_	_	_
7-9	1088-1089	a	abstract[56]	new[56]	_	_
7-10	1090-1094	plan	abstract[56]	new[56]	_	_
7-11	1095-1098	was	_	_	_	_
7-12	1099-1107	prepared	_	_	_	_
7-13	1108-1111	for	_	_	_	_
7-14	1112-1113	a	event[58]	new[58]	_	_
7-15	1114-1117	two	event[58]	new[58]	_	_
7-16	1118-1123	phase	abstract|event[58]	new|new[58]	_	_
7-17	1124-1132	approach	event[58]	new[58]	_	_
7-18	1133-1135	to	_	_	_	_
7-19	1136-1142	supply	_	_	_	_
7-20	1143-1153	sufficient	substance[59]	giv[59]	coref	8-19[0_59]
7-21	1154-1162	vaccines	substance[59]	giv[59]	_	_
7-22	1163-1166	for	substance[59]	giv[59]	_	_
7-23	1167-1169	10	substance[59]|abstract[60]	giv[59]|new[60]	appos	7-32[63_60]
7-24	1170-1171	%	substance[59]|abstract[60]	giv[59]|new[60]	_	_
7-25	1172-1174	of	substance[59]|abstract[60]	giv[59]|new[60]	_	_
7-26	1175-1178	the	substance[59]|abstract[60]|abstract[61]	giv[59]|new[60]|new[61]	_	_
7-27	1179-1189	population	substance[59]|abstract[60]|abstract[61]	giv[59]|new[60]|new[61]	_	_
7-28	1190-1192	in	substance[59]|abstract[60]|abstract[61]	giv[59]|new[60]|new[61]	_	_
7-29	1193-1198	these	substance[59]|abstract[60]|abstract[61]|place[62]	giv[59]|new[60]|new[61]|giv[62]	coref	9-4[82_62]
7-30	1199-1208	countries	substance[59]|abstract[60]|abstract[61]|place[62]	giv[59]|new[60]|new[61]|giv[62]	_	_
7-31	1209-1210	;	_	_	_	_
7-32	1211-1213	an	abstract[63]	giv[63]	_	_
7-33	1214-1221	initial	abstract[63]	giv[63]	_	_
7-34	1222-1228	supply	abstract[63]	giv[63]	_	_
7-35	1229-1231	to	_	_	_	_
7-36	1232-1237	cover	_	_	_	_
7-37	1238-1244	health	abstract|person[65]	new|new[65]	coref|coref	24-19|24-19
7-38	1245-1252	workers	person[65]	new[65]	_	_
7-39	1253-1256	and	_	_	_	_
7-40	1257-1262	other	person[66]	new[66]	_	_
7-41	1263-1272	essential	person[66]	new[66]	_	_
7-42	1273-1280	workers	person[66]	new[66]	_	_
7-43	1281-1282	,	person[66]	new[66]	_	_
7-44	1283-1293	equivalent	person[66]	new[66]	_	_
7-45	1294-1296	to	_	_	_	_
7-46	1297-1298	2	quantity[67]	new[67]	_	_
7-47	1299-1300	%	quantity[67]	new[67]	_	_
7-48	1301-1303	of	quantity[67]	new[67]	_	_
7-49	1304-1307	the	quantity[67]|person[68]	new[67]|new[68]	_	_
7-50	1308-1318	population	quantity[67]|person[68]	new[67]|new[68]	_	_
7-51	1319-1320	,	_	_	_	_
7-52	1321-1324	and	_	_	_	_
7-53	1325-1326	a	abstract[69]	new[69]	coref	8-4[0_69]
7-54	1327-1333	second	abstract[69]	new[69]	_	_
7-55	1334-1340	supply	abstract[69]	new[69]	_	_
7-56	1341-1343	of	abstract[69]	new[69]	_	_
7-57	1344-1345	8	abstract[69]|quantity[70]	new[69]|new[70]	_	_
7-58	1346-1347	%	abstract[69]|quantity[70]	new[69]|new[70]	_	_
7-59	1348-1351	for	abstract[69]|quantity[70]	new[69]|new[70]	_	_
7-60	1352-1357	other	abstract[69]|quantity[70]|person[72]	new[69]|new[70]|new[72]	coref	20-3[172_72]
7-61	1358-1366	priority	abstract[69]|quantity[70]|abstract|person[72]	new[69]|new[70]|new|new[72]	_	_
7-62	1367-1373	groups	abstract[69]|quantity[70]|person[72]	new[69]|new[70]|new[72]	_	_
7-63	1374-1375	.	_	_	_	_

#Text=The sequencing of supply was based on assessments of vulnerability to the pandemic , and readiness to utilize vaccines .
8-1	1376-1379	The	abstract[73]	new[73]	_	_
8-2	1380-1390	sequencing	abstract[73]	new[73]	_	_
8-3	1391-1393	of	abstract[73]	new[73]	_	_
8-4	1394-1400	supply	abstract[73]|abstract	new[73]|giv	_	_
8-5	1401-1404	was	_	_	_	_
8-6	1405-1410	based	_	_	_	_
8-7	1411-1413	on	_	_	_	_
8-8	1414-1425	assessments	abstract[75]|abstract[76]	new[75]|new[76]	ana|ana	10-9[0_76]|10-9[0_76]
8-9	1426-1428	of	abstract[75]|abstract[76]	new[75]|new[76]	_	_
8-10	1429-1442	vulnerability	abstract[75]|abstract[76]|abstract[77]	new[75]|new[76]|new[77]	_	_
8-11	1443-1445	to	abstract[75]|abstract[76]|abstract[77]	new[75]|new[76]|new[77]	_	_
8-12	1446-1449	the	abstract[75]|abstract[76]|abstract[77]|abstract[78]	new[75]|new[76]|new[77]|giv[78]	_	_
8-13	1450-1458	pandemic	abstract[75]|abstract[76]|abstract[77]|abstract[78]	new[75]|new[76]|new[77]|giv[78]	_	_
8-14	1459-1460	,	abstract[76]	new[76]	_	_
8-15	1461-1464	and	abstract[76]	new[76]	_	_
8-16	1465-1474	readiness	abstract[76]|abstract	new[76]|new	_	_
8-17	1475-1477	to	_	_	_	_
8-18	1478-1485	utilize	_	_	_	_
8-19	1486-1494	vaccines	substance	giv	coref	14-21[143_0]
8-20	1495-1496	.	_	_	_	_

#Text=To date , 25 countries have received donated H1N1 vaccine totaling more than 10 million doses , along with ancillary supplies .
9-1	1497-1499	To	_	_	_	_
9-2	1500-1504	date	time	new	_	_
9-3	1505-1506	,	_	_	_	_
9-4	1507-1509	25	place[82]	giv[82]	coref	10-4[88_82]
9-5	1510-1519	countries	place[82]	giv[82]	_	_
9-6	1520-1524	have	_	_	_	_
9-7	1525-1533	received	_	_	_	_
9-8	1534-1541	donated	substance[84]	giv[84]	coref	10-10[0_84]
9-9	1542-1546	H1N1	abstract|substance[84]	new|giv[84]	coref	12-13
9-10	1547-1554	vaccine	substance[84]	giv[84]	_	_
9-11	1555-1563	totaling	_	_	_	_
9-12	1564-1568	more	quantity[85]	new[85]	_	_
9-13	1569-1573	than	quantity[85]	new[85]	_	_
9-14	1574-1576	10	quantity[85]	new[85]	_	_
9-15	1577-1584	million	quantity[85]	new[85]	_	_
9-16	1585-1590	doses	quantity[85]	new[85]	_	_
9-17	1591-1592	,	_	_	_	_
9-18	1593-1598	along	_	_	_	_
9-19	1599-1603	with	_	_	_	_
9-20	1604-1613	ancillary	object[86]	new[86]	_	_
9-21	1614-1622	supplies	object[86]	new[86]	_	_
9-22	1623-1624	.	_	_	_	_

#Text=Another 15 to 20 countries will be receiving their vaccine shipments in the upcoming few weeks .
10-1	1625-1632	Another	place[87]	new[87]	_	_
10-2	1633-1635	15	place[87]	new[87]	_	_
10-3	1636-1638	to	place[87]	new[87]	_	_
10-4	1639-1641	20	place[87]|place[88]	new[87]|giv[88]	coref	11-1[93_88]
10-5	1642-1651	countries	place[87]|place[88]	new[87]|giv[88]	_	_
10-6	1652-1656	will	_	_	_	_
10-7	1657-1659	be	_	_	_	_
10-8	1660-1669	receiving	_	_	_	_
10-9	1670-1675	their	abstract|object[91]	giv|new[91]	coref|coref	11-7[0_91]|11-7[0_91]
10-10	1676-1683	vaccine	substance|object[91]	giv|new[91]	coref	13-18
10-11	1684-1693	shipments	object[91]	new[91]	_	_
10-12	1694-1696	in	_	_	_	_
10-13	1697-1700	the	time[92]	new[92]	_	_
10-14	1701-1709	upcoming	time[92]	new[92]	_	_
10-15	1710-1713	few	time[92]	new[92]	_	_
10-16	1714-1719	weeks	time[92]	new[92]	_	_
10-17	1720-1721	.	_	_	_	_

#Text=The 25 countries who have received shipments are : Azerbaijan , Afghanistan , Cambodia , Fiji , Kiribati , Kosovo , Laos PDR , Maldives , Mongolia , Nauru , Nicaragua , Papua New Guinea , Solomon Islands , Togo , Tonga , Vanuatu , Cuba , Honduras , El Salvador , Kenya , Samoa , Tokelau , Cook Islands , Pakistan , [ and ] Philippines
11-1	1722-1725	The	place[93]	giv[93]	coref	11-10[95_93]
11-2	1726-1728	25	place[93]	giv[93]	_	_
11-3	1729-1738	countries	place[93]	giv[93]	_	_
11-4	1739-1742	who	_	_	_	_
11-5	1743-1747	have	_	_	_	_
11-6	1748-1756	received	_	_	_	_
11-7	1757-1766	shipments	object	giv	_	_
11-8	1767-1770	are	_	_	_	_
11-9	1771-1772	:	_	_	_	_
11-10	1773-1783	Azerbaijan	place[95]	giv[95]	_	_
11-11	1784-1785	,	place[95]	giv[95]	_	_
11-12	1786-1797	Afghanistan	place[95]|place	giv[95]|new	_	_
11-13	1798-1799	,	place[95]	giv[95]	_	_
11-14	1800-1808	Cambodia	place[95]|place	giv[95]|new	_	_
11-15	1809-1810	,	place[95]	giv[95]	_	_
11-16	1811-1815	Fiji	place[95]|place	giv[95]|new	_	_
11-17	1816-1817	,	place[95]	giv[95]	_	_
11-18	1818-1826	Kiribati	place[95]|place	giv[95]|new	_	_
11-19	1827-1828	,	place[95]	giv[95]	_	_
11-20	1829-1835	Kosovo	place[95]|place	giv[95]|new	_	_
11-21	1836-1837	,	place[95]	giv[95]	_	_
11-22	1838-1842	Laos	place[95]|place|place[102]	giv[95]|new|new[102]	_	_
11-23	1843-1846	PDR	place[95]|place[102]	giv[95]|new[102]	_	_
11-24	1847-1848	,	place[95]	giv[95]	_	_
11-25	1849-1857	Maldives	place[95]|place	giv[95]|new	_	_
11-26	1858-1859	,	place[95]	giv[95]	_	_
11-27	1860-1868	Mongolia	place[95]|place	giv[95]|new	_	_
11-28	1869-1870	,	place[95]	giv[95]	_	_
11-29	1871-1876	Nauru	place[95]|place	giv[95]|new	_	_
11-30	1877-1878	,	place[95]	giv[95]	_	_
11-31	1879-1888	Nicaragua	place[95]|place	giv[95]|new	_	_
11-32	1889-1890	,	place[95]	giv[95]	_	_
11-33	1891-1896	Papua	place[95]|place[107]	giv[95]|new[107]	_	_
11-34	1897-1900	New	place[95]|place[107]	giv[95]|new[107]	_	_
11-35	1901-1907	Guinea	place[95]|place[107]	giv[95]|new[107]	_	_
11-36	1908-1909	,	place[95]	giv[95]	_	_
11-37	1910-1917	Solomon	place[95]|place[108]	giv[95]|new[108]	coref	11-59[118_108]
11-38	1918-1925	Islands	place[95]|place[108]	giv[95]|new[108]	_	_
11-39	1926-1927	,	place[95]	giv[95]	_	_
11-40	1928-1932	Togo	place[95]|place	giv[95]|new	_	_
11-41	1933-1934	,	place[95]	giv[95]	_	_
11-42	1935-1940	Tonga	place[95]|place	giv[95]|new	_	_
11-43	1941-1942	,	place[95]	giv[95]	_	_
11-44	1943-1950	Vanuatu	place[95]|place	giv[95]|new	_	_
11-45	1951-1952	,	place[95]	giv[95]	_	_
11-46	1953-1957	Cuba	place[95]|place	giv[95]|new	_	_
11-47	1958-1959	,	place[95]	giv[95]	_	_
11-48	1960-1968	Honduras	place[95]|place	giv[95]|new	_	_
11-49	1969-1970	,	place[95]	giv[95]	_	_
11-50	1971-1973	El	place[95]|place[114]	giv[95]|new[114]	_	_
11-51	1974-1982	Salvador	place[95]|place[114]	giv[95]|new[114]	_	_
11-52	1983-1984	,	place[95]	giv[95]	_	_
11-53	1985-1990	Kenya	place[95]|place	giv[95]|new	_	_
11-54	1991-1992	,	place[95]	giv[95]	_	_
11-55	1993-1998	Samoa	place[95]|place	giv[95]|new	_	_
11-56	1999-2000	,	place[95]	giv[95]	_	_
11-57	2001-2008	Tokelau	place[95]|place	giv[95]|new	_	_
11-58	2009-2010	,	place[95]	giv[95]	_	_
11-59	2011-2015	Cook	place[95]|place[118]	giv[95]|giv[118]	_	_
11-60	2016-2023	Islands	place[95]|place[118]	giv[95]|giv[118]	_	_
11-61	2024-2025	,	place[95]	giv[95]	_	_
11-62	2026-2034	Pakistan	place[95]|place	giv[95]|new	_	_
11-63	2035-2036	,	place[95]	giv[95]	_	_
11-64	2037-2038	[	place[95]	giv[95]	_	_
11-65	2039-2042	and	place[95]	giv[95]	_	_
11-66	2043-2044	]	place[95]	giv[95]	_	_
11-67	2045-2056	Philippines	place[95]|place	giv[95]|new	_	_

#Text=( ( MM ) ) Last November , the WHO stated the H1N1 virus is world 's most dominant virus . Is this still true ?
12-1	2057-2058	(	_	_	_	_
12-2	2059-2060	(	_	_	_	_
12-3	2061-2063	MM	person	giv	coref	17-3
12-4	2064-2065	)	_	_	_	_
12-5	2066-2067	)	_	_	_	_
12-6	2068-2072	Last	person|time[123]	new|new[123]	_	_
12-7	2073-2081	November	time[123]	new[123]	_	_
12-8	2082-2083	,	_	_	_	_
12-9	2084-2087	the	_	_	_	_
12-10	2088-2091	WHO	_	_	_	_
12-11	2092-2098	stated	_	_	_	_
12-12	2099-2102	the	abstract[125]	new[125]	_	_
12-13	2103-2107	H1N1	object|abstract[125]	giv|new[125]	coref	15-32
12-14	2108-2113	virus	abstract[125]	new[125]	_	_
12-15	2114-2116	is	_	_	_	_
12-16	2117-2122	world	place[126]|abstract[127]	new[126]|new[127]	ana|coref|ana|coref	12-23[0_127]|15-27[149_126]|12-23[0_127]|15-27[149_126]
12-17	2123-2125	's	place[126]|abstract[127]	new[126]|new[127]	_	_
12-18	2126-2130	most	abstract[127]	new[127]	_	_
12-19	2131-2139	dominant	abstract[127]	new[127]	_	_
12-20	2140-2145	virus	abstract[127]	new[127]	_	_
12-21	2146-2147	.	_	_	_	_
12-22	2148-2150	Is	_	_	_	_
12-23	2151-2155	this	abstract	giv	coref	15-32[152_0]
12-24	2156-2161	still	_	_	_	_
12-25	2162-2166	true	_	_	_	_
12-26	2167-2168	?	_	_	_	_

#Text=( ( KM ) ) On February 18th , WHO concluded a four-day meeting to look at vaccine strains for seasonal influenza vaccine for the 2010 and 2011 season .
13-1	2169-2170	(	_	_	_	_
13-2	2171-2172	(	_	_	_	_
13-3	2173-2175	KM	quantity	giv	coref	18-3
13-4	2176-2177	)	_	_	_	_
13-5	2178-2179	)	_	_	_	_
13-6	2180-2182	On	_	_	_	_
13-7	2183-2191	February	time	new	coref	15-11
13-8	2192-2196	18th	_	_	_	_
13-9	2197-2198	,	_	_	_	_
13-10	2199-2202	WHO	_	_	_	_
13-11	2203-2212	concluded	_	_	_	_
13-12	2213-2214	a	event[131]	new[131]	ana	14-1[0_131]
13-13	2215-2223	four-day	event[131]	new[131]	_	_
13-14	2224-2231	meeting	event[131]	new[131]	_	_
13-15	2232-2234	to	_	_	_	_
13-16	2235-2239	look	_	_	_	_
13-17	2240-2242	at	_	_	_	_
13-18	2243-2250	vaccine	substance|abstract[133]	giv|new[133]	coref|coref|coref|coref	13-21[135_0]|14-15[140_133]|13-21[135_0]|14-15[140_133]
13-19	2251-2258	strains	abstract[133]	new[133]	_	_
13-20	2259-2262	for	abstract[133]	new[133]	_	_
13-21	2263-2271	seasonal	abstract[133]|substance[135]	new[133]|giv[135]	coref	14-15[0_135]
13-22	2272-2281	influenza	abstract[133]|abstract|substance[135]	new[133]|giv|giv[135]	coref	14-27
13-23	2282-2289	vaccine	abstract[133]|substance[135]	new[133]|giv[135]	_	_
13-24	2290-2293	for	abstract[133]|substance[135]	new[133]|giv[135]	_	_
13-25	2294-2297	the	abstract[133]|substance[135]|time[136]	new[133]|giv[135]|new[136]	coref	16-29[161_136]
13-26	2298-2302	2010	abstract[133]|substance[135]|time[136]	new[133]|giv[135]|new[136]	_	_
13-27	2303-2306	and	abstract[133]|substance[135]|time[136]	new[133]|giv[135]|new[136]	_	_
13-28	2307-2311	2011	abstract[133]|substance[135]|time[136]	new[133]|giv[135]|new[136]	_	_
13-29	2312-2318	season	abstract[133]|substance[135]|time[136]	new[133]|giv[135]|new[136]	_	_
13-30	2319-2320	.	_	_	_	_

#Text=This is part of the routine work that WHO does twice yearly to determine vaccine strains to be included in upcoming northern and southern hemisphere seasonal influenza vaccines .
14-1	2321-2325	This	event	giv	_	_
14-2	2326-2328	is	_	_	_	_
14-3	2329-2333	part	_	_	_	_
14-4	2334-2336	of	_	_	_	_
14-5	2337-2340	the	abstract[138]	new[138]	ana	15-13[0_138]
14-6	2341-2348	routine	abstract[138]	new[138]	_	_
14-7	2349-2353	work	abstract[138]	new[138]	_	_
14-8	2354-2358	that	_	_	_	_
14-9	2359-2362	WHO	_	_	_	_
14-10	2363-2367	does	_	_	_	_
14-11	2368-2373	twice	_	_	_	_
14-12	2374-2380	yearly	_	_	_	_
14-13	2381-2383	to	_	_	_	_
14-14	2384-2393	determine	_	_	_	_
14-15	2394-2401	vaccine	substance|abstract[140]	giv|giv[140]	coref|coref	24-12[203_0]|24-12[203_0]
14-16	2402-2409	strains	abstract[140]	giv[140]	_	_
14-17	2410-2412	to	_	_	_	_
14-18	2413-2415	be	_	_	_	_
14-19	2416-2424	included	_	_	_	_
14-20	2425-2427	in	_	_	_	_
14-21	2428-2436	upcoming	substance[143]	giv[143]	_	_
14-22	2437-2445	northern	substance[143]	giv[143]	_	_
14-23	2446-2449	and	substance[143]	giv[143]	_	_
14-24	2450-2458	southern	substance[143]	giv[143]	_	_
14-25	2459-2469	hemisphere	abstract|substance[143]	new|giv[143]	_	_
14-26	2470-2478	seasonal	substance[143]	giv[143]	_	_
14-27	2479-2488	influenza	abstract|substance[143]	giv|giv[143]	coref	21-25[185_0]
14-28	2489-2497	vaccines	substance[143]	giv[143]	_	_
14-29	2498-2499	.	_	_	_	_

#Text=During the scientific discussions which ended on the 18th of February , it was confirmed that the overwhelming number of influenza viruses that were isolated around the world were the pandemic H1N1 virus .
15-1	2500-2506	During	_	_	_	_
15-2	2507-2510	the	event[144]	new[144]	_	_
15-3	2511-2521	scientific	event[144]	new[144]	_	_
15-4	2522-2533	discussions	event[144]	new[144]	_	_
15-5	2534-2539	which	_	_	_	_
15-6	2540-2545	ended	_	_	_	_
15-7	2546-2548	on	_	_	_	_
15-8	2549-2552	the	_	_	_	_
15-9	2553-2557	18th	_	_	_	_
15-10	2558-2560	of	_	_	_	_
15-11	2561-2569	February	time	giv	_	_
15-12	2570-2571	,	_	_	_	_
15-13	2572-2574	it	abstract	giv	_	_
15-14	2575-2578	was	_	_	_	_
15-15	2579-2588	confirmed	_	_	_	_
15-16	2589-2593	that	_	_	_	_
15-17	2594-2597	the	abstract[147]	new[147]	coref	15-30[150_147]
15-18	2598-2610	overwhelming	abstract[147]	new[147]	_	_
15-19	2611-2617	number	abstract[147]	new[147]	_	_
15-20	2618-2620	of	abstract[147]	new[147]	_	_
15-21	2621-2630	influenza	abstract[147]|object[148]	new[147]|new[148]	coref	16-18[157_148]
15-22	2631-2638	viruses	abstract[147]|object[148]	new[147]|new[148]	_	_
15-23	2639-2643	that	_	_	_	_
15-24	2644-2648	were	_	_	_	_
15-25	2649-2657	isolated	_	_	_	_
15-26	2658-2664	around	_	_	_	_
15-27	2665-2668	the	place[149]	giv[149]	_	_
15-28	2669-2674	world	place[149]	giv[149]	_	_
15-29	2675-2679	were	_	_	_	_
15-30	2680-2683	the	abstract[150]	giv[150]	coref	16-16[156_150]
15-31	2684-2692	pandemic	abstract[150]	giv[150]	_	_
15-32	2693-2697	H1N1	abstract[150]|abstract|abstract[152]	giv[150]|giv|giv[152]	coref|coref|coref|coref	16-10[155_152]|17-23[165_0]|16-10[155_152]|17-23[165_0]
15-33	2698-2703	virus	abstract[150]|abstract[152]	giv[150]|giv[152]	_	_
15-34	2704-2705	.	_	_	_	_

#Text=The experts believe that based on this information that this virus will continue to be one of the dominant viruses in wide circulation in the coming fall and winter season .
16-1	2706-2709	The	person[153]	new[153]	_	_
16-2	2710-2717	experts	person[153]	new[153]	_	_
16-3	2718-2725	believe	_	_	_	_
16-4	2726-2730	that	_	_	_	_
16-5	2731-2736	based	_	_	_	_
16-6	2737-2739	on	_	_	_	_
16-7	2740-2744	this	abstract[154]	new[154]	_	_
16-8	2745-2756	information	abstract[154]	new[154]	_	_
16-9	2757-2761	that	_	_	_	_
16-10	2762-2766	this	abstract[155]	giv[155]	coref	24-24[208_155]
16-11	2767-2772	virus	abstract[155]	giv[155]	_	_
16-12	2773-2777	will	_	_	_	_
16-13	2778-2786	continue	_	_	_	_
16-14	2787-2789	to	_	_	_	_
16-15	2790-2792	be	_	_	_	_
16-16	2793-2796	one	abstract[156]	giv[156]	coref	19-5[168_156]
16-17	2797-2799	of	abstract[156]	giv[156]	_	_
16-18	2800-2803	the	abstract[156]|object[157]	giv[156]|giv[157]	_	_
16-19	2804-2812	dominant	abstract[156]|object[157]	giv[156]|giv[157]	_	_
16-20	2813-2820	viruses	abstract[156]|object[157]	giv[156]|giv[157]	_	_
16-21	2821-2823	in	abstract[156]|object[157]	giv[156]|giv[157]	_	_
16-22	2824-2828	wide	abstract[156]|object[157]|abstract[158]	giv[156]|giv[157]|new[158]	_	_
16-23	2829-2840	circulation	abstract[156]|object[157]|abstract[158]	giv[156]|giv[157]|new[158]	_	_
16-24	2841-2843	in	abstract[156]|object[157]|abstract[158]	giv[156]|giv[157]|new[158]	_	_
16-25	2844-2847	the	abstract[156]|object[157]|abstract[158]|time[159]	giv[156]|giv[157]|new[158]|new[159]	_	_
16-26	2848-2854	coming	abstract[156]|object[157]|abstract[158]|time[159]	giv[156]|giv[157]|new[158]|new[159]	_	_
16-27	2855-2859	fall	abstract[156]|object[157]|abstract[158]|time[159]	giv[156]|giv[157]|new[158]|new[159]	_	_
16-28	2860-2863	and	abstract[156]|object[157]|abstract[158]	giv[156]|giv[157]|new[158]	_	_
16-29	2864-2870	winter	abstract[156]|object[157]|abstract[158]|abstract|time[161]	giv[156]|giv[157]|new[158]|new|giv[161]	_	_
16-30	2871-2877	season	abstract[156]|object[157]|abstract[158]|time[161]	giv[156]|giv[157]|new[158]|giv[161]	_	_
16-31	2878-2879	.	_	_	_	_

#Text=( ( MM ) ) Is there anything that the WHO believes to be very important for the public to know about the H1N1 ?
17-1	2880-2881	(	_	_	_	_
17-2	2882-2883	(	_	_	_	_
17-3	2884-2886	MM	person	giv	_	_
17-4	2887-2888	)	_	_	_	_
17-5	2889-2890	)	_	_	_	_
17-6	2891-2893	Is	_	_	_	_
17-7	2894-2899	there	_	_	_	_
17-8	2900-2908	anything	abstract	new	_	_
17-9	2909-2913	that	_	_	_	_
17-10	2914-2917	the	_	_	_	_
17-11	2918-2921	WHO	_	_	_	_
17-12	2922-2930	believes	_	_	_	_
17-13	2931-2933	to	_	_	_	_
17-14	2934-2936	be	_	_	_	_
17-15	2937-2941	very	_	_	_	_
17-16	2942-2951	important	_	_	_	_
17-17	2952-2955	for	_	_	_	_
17-18	2956-2959	the	person[164]	new[164]	_	_
17-19	2960-2966	public	person[164]	new[164]	_	_
17-20	2967-2969	to	_	_	_	_
17-21	2970-2974	know	_	_	_	_
17-22	2975-2980	about	_	_	_	_
17-23	2981-2984	the	abstract[165]	giv[165]	coref	24-13[0_165]
17-24	2985-2989	H1N1	abstract[165]	giv[165]	_	_
17-25	2990-2991	?	_	_	_	_

#Text=( ( KM ) )
18-1	2992-2993	(	_	_	_	_
18-2	2994-2995	(	_	_	_	_
18-3	2996-2998	KM	quantity	giv	_	_
18-4	2999-3000	)	_	_	_	_
18-5	3001-3002	)	_	_	_	_

#Text=The overall impact of the pandemic has been moderate and most people experienced mild symptoms or illness .
19-1	3003-3006	The	abstract[167]	new[167]	_	_
19-2	3007-3014	overall	abstract[167]	new[167]	_	_
19-3	3015-3021	impact	abstract[167]	new[167]	_	_
19-4	3022-3024	of	abstract[167]	new[167]	_	_
19-5	3025-3028	the	abstract[167]|abstract[168]	new[167]|giv[168]	coref	23-7[193_168]
19-6	3029-3037	pandemic	abstract[167]|abstract[168]	new[167]|giv[168]	_	_
19-7	3038-3041	has	_	_	_	_
19-8	3042-3046	been	_	_	_	_
19-9	3047-3055	moderate	_	_	_	_
19-10	3056-3059	and	_	_	_	_
19-11	3060-3064	most	person[169]	new[169]	coref	20-29[179_169]
19-12	3065-3071	people	person[169]	new[169]	_	_
19-13	3072-3083	experienced	_	_	_	_
19-14	3084-3088	mild	abstract[170]	new[170]	_	_
19-15	3089-3097	symptoms	abstract[170]	new[170]	_	_
19-16	3098-3100	or	_	_	_	_
19-17	3101-3108	illness	abstract	new	coref	20-16[175_0]
19-18	3109-3110	.	_	_	_	_

#Text=However , some groups are more vulnerable and have a higher risk of complications or severe illness , for example pregnant women , infants , young children and people with chronic diseases .
20-1	3111-3118	However	_	_	_	_
20-2	3119-3120	,	_	_	_	_
20-3	3121-3125	some	person[172]	giv[172]	_	_
20-4	3126-3132	groups	person[172]	giv[172]	_	_
20-5	3133-3136	are	_	_	_	_
20-6	3137-3141	more	_	_	_	_
20-7	3142-3152	vulnerable	_	_	_	_
20-8	3153-3156	and	_	_	_	_
20-9	3157-3161	have	_	_	_	_
20-10	3162-3163	a	abstract[173]	new[173]	_	_
20-11	3164-3170	higher	abstract[173]	new[173]	_	_
20-12	3171-3175	risk	abstract[173]	new[173]	_	_
20-13	3176-3178	of	abstract[173]	new[173]	_	_
20-14	3179-3192	complications	abstract[173]|abstract	new[173]|new	_	_
20-15	3193-3195	or	abstract[173]	new[173]	_	_
20-16	3196-3202	severe	abstract[173]|abstract[175]	new[173]|giv[175]	coref	24-32[0_175]
20-17	3203-3210	illness	abstract[173]|abstract[175]	new[173]|giv[175]	_	_
20-18	3211-3212	,	_	_	_	_
20-19	3213-3216	for	_	_	_	_
20-20	3217-3224	example	_	_	_	_
20-21	3225-3233	pregnant	person[176]	new[176]	_	_
20-22	3234-3239	women	person[176]	new[176]	_	_
20-23	3240-3241	,	_	_	_	_
20-24	3242-3249	infants	person	new	_	_
20-25	3250-3251	,	_	_	_	_
20-26	3252-3257	young	person[178]	giv[178]	_	_
20-27	3258-3266	children	person[178]	giv[178]	_	_
20-28	3267-3270	and	_	_	_	_
20-29	3271-3277	people	person[179]	giv[179]	coref	23-13[196_179]
20-30	3278-3282	with	person[179]	giv[179]	_	_
20-31	3283-3290	chronic	person[179]|abstract[180]	giv[179]|new[180]	_	_
20-32	3291-3299	diseases	person[179]|abstract[180]	giv[179]|new[180]	_	_
20-33	3300-3301	.	_	_	_	_

#Text=Many of the severe cases have been due to viral pneumonia , which is harder to treat than the bacterial pneumonia normally associated with seasonal influenza .
21-1	3302-3306	Many	_	_	_	_
21-2	3307-3309	of	_	_	_	_
21-3	3310-3313	the	abstract[181]	new[181]	_	_
21-4	3314-3320	severe	abstract[181]	new[181]	_	_
21-5	3321-3326	cases	abstract[181]	new[181]	_	_
21-6	3327-3331	have	_	_	_	_
21-7	3332-3336	been	_	_	_	_
21-8	3337-3340	due	_	_	_	_
21-9	3341-3343	to	_	_	_	_
21-10	3344-3349	viral	abstract[182]	new[182]	coref	21-19[184_182]
21-11	3350-3359	pneumonia	abstract[182]	new[182]	_	_
21-12	3360-3361	,	_	_	_	_
21-13	3362-3367	which	_	_	_	_
21-14	3368-3370	is	_	_	_	_
21-15	3371-3377	harder	_	_	_	_
21-16	3378-3380	to	_	_	_	_
21-17	3381-3386	treat	_	_	_	_
21-18	3387-3391	than	_	_	_	_
21-19	3392-3395	the	abstract[184]	giv[184]	_	_
21-20	3396-3405	bacterial	object|abstract[184]	new|giv[184]	_	_
21-21	3406-3415	pneumonia	abstract[184]	giv[184]	_	_
21-22	3416-3424	normally	_	_	_	_
21-23	3425-3435	associated	_	_	_	_
21-24	3436-3440	with	_	_	_	_
21-25	3441-3449	seasonal	abstract[185]	giv[185]	coref	23-9[0_185]
21-26	3450-3459	influenza	abstract[185]	giv[185]	_	_
21-27	3460-3461	.	_	_	_	_

#Text=Many of these patients have required intensive care , which has led to intensive care units being frequently overwhelmed at the peak of the outbreak .
22-1	3462-3466	Many	_	_	_	_
22-2	3467-3469	of	_	_	_	_
22-3	3470-3475	these	person[186]	new[186]	_	_
22-4	3476-3484	patients	person[186]	new[186]	_	_
22-5	3485-3489	have	_	_	_	_
22-6	3490-3498	required	_	_	_	_
22-7	3499-3508	intensive	abstract[187]	new[187]	coref	22-15[0_187]
22-8	3509-3513	care	abstract[187]	new[187]	_	_
22-9	3514-3515	,	_	_	_	_
22-10	3516-3521	which	_	_	_	_
22-11	3522-3525	has	_	_	_	_
22-12	3526-3529	led	_	_	_	_
22-13	3530-3532	to	_	_	_	_
22-14	3533-3542	intensive	place[189]	new[189]	_	_
22-15	3543-3547	care	abstract|place[189]	giv|new[189]	_	_
22-16	3548-3553	units	place[189]	new[189]	_	_
22-17	3554-3559	being	_	_	_	_
22-18	3560-3570	frequently	_	_	_	_
22-19	3571-3582	overwhelmed	_	_	_	_
22-20	3583-3585	at	_	_	_	_
22-21	3586-3589	the	event[190]	new[190]	_	_
22-22	3590-3594	peak	event[190]	new[190]	_	_
22-23	3595-3597	of	event[190]	new[190]	_	_
22-24	3598-3601	the	event[190]|abstract[191]	new[190]|new[191]	_	_
22-25	3602-3610	outbreak	event[190]|abstract[191]	new[190]|new[191]	_	_
22-26	3611-3612	.	_	_	_	_

#Text=Most of the deaths caused by the pandemic influenza disease occurred among younger people than is the case during seasonal influenza outbreaks , including among those who were previously healthy .
23-1	3613-3617	Most	event[192]	new[192]	_	_
23-2	3618-3620	of	event[192]	new[192]	_	_
23-3	3621-3624	the	event[192]	new[192]	_	_
23-4	3625-3631	deaths	event[192]	new[192]	_	_
23-5	3632-3638	caused	_	_	_	_
23-6	3639-3641	by	_	_	_	_
23-7	3642-3645	the	abstract[193]	giv[193]	coref	24-25[0_193]
23-8	3646-3654	pandemic	abstract[193]	giv[193]	_	_
23-9	3655-3664	influenza	abstract|abstract[195]	giv|new[195]	coref|coref	23-21|23-21
23-10	3665-3672	disease	abstract[195]	new[195]	_	_
23-11	3673-3681	occurred	_	_	_	_
23-12	3682-3687	among	_	_	_	_
23-13	3688-3695	younger	person[196]	giv[196]	coref	24-3[0_196]
23-14	3696-3702	people	person[196]	giv[196]	_	_
23-15	3703-3707	than	_	_	_	_
23-16	3708-3710	is	_	_	_	_
23-17	3711-3714	the	_	_	_	_
23-18	3715-3719	case	_	_	_	_
23-19	3720-3726	during	_	_	_	_
23-20	3727-3735	seasonal	event[198]	new[198]	_	_
23-21	3736-3745	influenza	abstract|event[198]	giv|new[198]	_	_
23-22	3746-3755	outbreaks	event[198]	new[198]	_	_
23-23	3756-3757	,	_	_	_	_
23-24	3758-3767	including	_	_	_	_
23-25	3768-3773	among	_	_	_	_
23-26	3774-3779	those	_	_	_	_
23-27	3780-3783	who	_	_	_	_
23-28	3784-3788	were	_	_	_	_
23-29	3789-3799	previously	_	_	_	_
23-30	3800-3807	healthy	_	_	_	_
23-31	3808-3809	.	_	_	_	_

#Text=To protect people from infection and avoid related severe outcomes , the H1N1 vaccine is an important public health tool as long as the pandemic H1N1 virus is circulating and causing illness .
24-1	3810-3812	To	_	_	_	_
24-2	3813-3820	protect	_	_	_	_
24-3	3821-3827	people	person	giv	_	_
24-4	3828-3832	from	_	_	_	_
24-5	3833-3842	infection	abstract	new	_	_
24-6	3843-3846	and	_	_	_	_
24-7	3847-3852	avoid	_	_	_	_
24-8	3853-3860	related	abstract[201]	new[201]	_	_
24-9	3861-3867	severe	abstract[201]	new[201]	_	_
24-10	3868-3876	outcomes	abstract[201]	new[201]	_	_
24-11	3877-3878	,	_	_	_	_
24-12	3879-3882	the	substance[203]	giv[203]	coref	24-16[205_203]
24-13	3883-3887	H1N1	abstract|substance[203]	giv|giv[203]	coref	24-26
24-14	3888-3895	vaccine	substance[203]	giv[203]	_	_
24-15	3896-3898	is	_	_	_	_
24-16	3899-3901	an	substance[205]	giv[205]	coref	25-27[220_205]
24-17	3902-3911	important	substance[205]	giv[205]	_	_
24-18	3912-3918	public	substance[205]	giv[205]	_	_
24-19	3919-3925	health	abstract|substance[205]	giv|giv[205]	_	_
24-20	3926-3930	tool	substance[205]	giv[205]	_	_
24-21	3931-3933	as	substance[205]	giv[205]	_	_
24-22	3934-3938	long	substance[205]	giv[205]	_	_
24-23	3939-3941	as	_	_	_	_
24-24	3942-3945	the	abstract[208]	giv[208]	_	_
24-25	3946-3954	pandemic	event|abstract[208]	giv|giv[208]	coref	25-22[218_0]
24-26	3955-3959	H1N1	object|abstract[208]	giv|giv[208]	coref	25-25
24-27	3960-3965	virus	abstract[208]	giv[208]	_	_
24-28	3966-3968	is	_	_	_	_
24-29	3969-3980	circulating	_	_	_	_
24-30	3981-3984	and	_	_	_	_
24-31	3985-3992	causing	_	_	_	_
24-32	3993-4000	illness	abstract	giv	_	_
24-33	4001-4002	.	_	_	_	_

#Text=Since September 2009 , more than 75 Member States and territories have implemented immunization programmes , and 290 million doses of the pandemic ( H1N1 ) 2009 vaccine have been administered .
25-1	4003-4008	Since	_	_	_	_
25-2	4009-4018	September	time[210]	new[210]	_	_
25-3	4019-4023	2009	time[210]|time	new[210]|giv	_	_
25-4	4024-4025	,	_	_	_	_
25-5	4026-4030	more	_	_	_	_
25-6	4031-4035	than	_	_	_	_
25-7	4036-4038	75	place[213]	new[213]	_	_
25-8	4039-4045	Member	person|place[213]	new|new[213]	_	_
25-9	4046-4052	States	place[213]	new[213]	_	_
25-10	4053-4056	and	_	_	_	_
25-11	4057-4068	territories	place	new	_	_
25-12	4069-4073	have	_	_	_	_
25-13	4074-4085	implemented	_	_	_	_
25-14	4086-4098	immunization	quantity|abstract[216]	new|new[216]	_	_
25-15	4099-4109	programmes	abstract[216]	new[216]	_	_
25-16	4110-4111	,	_	_	_	_
25-17	4112-4115	and	_	_	_	_
25-18	4116-4119	290	quantity[217]	new[217]	_	_
25-19	4120-4127	million	quantity[217]	new[217]	_	_
25-20	4128-4133	doses	quantity[217]	new[217]	_	_
25-21	4134-4136	of	quantity[217]	new[217]	_	_
25-22	4137-4140	the	quantity[217]|abstract[218]	new[217]|giv[218]	_	_
25-23	4141-4149	pandemic	quantity[217]|abstract[218]	new[217]|giv[218]	_	_
25-24	4150-4151	(	_	_	_	_
25-25	4152-4156	H1N1	abstract	giv	_	_
25-26	4157-4158	)	_	_	_	_
25-27	4159-4163	2009	substance[220]	giv[220]	_	_
25-28	4164-4171	vaccine	substance[220]	giv[220]	_	_
25-29	4172-4176	have	_	_	_	_
25-30	4177-4181	been	_	_	_	_
25-31	4182-4194	administered	_	_	_	_
25-32	4195-4196	.	_	_	_	_
